Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials

被引:2290
作者
Sylvester, RJ [1 ]
van der Meijden, APM
Oosterlinck, W
Witjes, JA
Bouffioux, C
Denis, L
Newling, DWW
Kurth, K
机构
[1] EORTC Data Ctr, Brussels, Belgium
[2] Jeroen Bosch Hosp, Dept Urol, Shertogenbosch, Netherlands
[3] State Univ Ghent Hosp, Dept Urol, B-9000 Ghent, Belgium
[4] Radboud Univ, Med Ctr, Dept Urol, Nijmegen, Netherlands
[5] CHU Sart Tilman, Dept Urol, B-4000 Liege, Belgium
[6] Middelheim Hosp, Dept Urol, Antwerp, Belgium
[7] Free Univ Amsterdam, Med Ctr, Dept Urol, Amsterdam, Netherlands
[8] Acad Med Ctr, Dept Urol, Amsterdam, Netherlands
关键词
superficial bladder cancer; prognostic factors; recurrence; progression; cystectomy; prediction;
D O I
10.1016/j.eururo.2005.12.031
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection. Methods: A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials. Results: A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%. Conclusions: With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:466 / 477
页数:12
相关论文
共 48 条
  • [1] Allard P, 1998, BRIT J UROL, V81, P692
  • [2] Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer:: prognostic factors for time to recurrence and progression
    Andius, P
    Holmäng, S
    [J]. BJU INTERNATIONAL, 2004, 93 (07) : 980 - 984
  • [3] The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma
    Bernardini, S
    Billerey, C
    Martin, M
    Adessi, GL
    Wallerand, H
    Bittard, H
    [J]. JOURNAL OF UROLOGY, 2001, 165 (01) : 42 - 46
  • [4] Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity
    Böhle, A
    Jocham, D
    Bock, PR
    [J]. JOURNAL OF UROLOGY, 2003, 169 (01) : 90 - 95
  • [5] INTRAVESICAL ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL TRANSITIONAL-CELL BLADDER-CARCINOMA - RESULTS OF 2 EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER RANDOMIZED TRIALS WITH MITOMYCIN-C AND DOXORUBICIN COMPARING EARLY VERSUS DELAYED INSTILLATIONS AND SHORT-TERM VERSUS LONG-TERM TREATMENT
    BOUFFIOUX, C
    KURTH, KH
    BONO, A
    OOSTERLINCK, W
    KRUGER, CB
    DEPAUW, M
    SYLVESTER, R
    DENIS, L
    NEWLING, D
    HALL, R
    BRESSEL, M
    CASSELMAN, J
    SMITH, P
    ROBINSON, M
    KEUPPENS, F
    TOLLEY, D
    JAKSE, G
    BOLLACK, C
    VERGISON, B
    HOEKSTRA, W
    DASILVA, FC
    GROEN, J
    RICHARDS, B
    PAVONEMACALUSO, M
    VANDERMEIJDEN, A
    ZWARTENDIJK, H
    JACOBI, G
    VANCAUBERG, R
    SCHRODER, F
    HIRDES, D
    LEISINGER, H
    RIEDL, H
    LUDWIG, P
    ROOZENDAAL, K
    MARECHAL, L
    VANAUBEL, O
    CONSIDINE, J
    DEBRUYNE, F
    CARREIRA, F
    DEWALL, D
    MENSINK, H
    VIGGIANO, G
    [J]. JOURNAL OF UROLOGY, 1995, 153 (03) : 934 - 941
  • [6] ADJUVANT CHEMOTHERAPY OF RECURRENT SUPERFICIAL TRANSITIONAL CELL-CARCINOMA - RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING INTRAVESICAL INSTILLATION OF THIOTEPA, DOXORUBICIN AND CISPLATIN
    BOUFFIOUX, C
    DENIS, L
    OOSTERLINCK, W
    VIGGIANO, G
    VERGISON, B
    KEUPPENS, F
    DEPAUW, M
    SYLVESTER, R
    CHEUVART, B
    [J]. JOURNAL OF UROLOGY, 1992, 148 (02) : 297 - 301
  • [7] ANALYSIS OF THE PROBABILITY AND RISK OF CAUSE-SPECIFIC FAILURE
    CAPLAN, RJ
    PAJAK, TF
    COX, JD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (05): : 1183 - 1186
  • [8] PROGNOSTIC FACTORS IN SUPERFICIAL BLADDER-TUMORS - A STUDY OF THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER - GENITOURINARY TRACT CANCER COOPERATIVE GROUP
    DALESIO, O
    SCHULMAN, CC
    SYLVESTER, R
    DEPAUW, M
    ROBINSON, M
    DENIS, L
    SMITH, P
    VIGGIANO, G
    SOLOWAY, MS
    [J]. JOURNAL OF UROLOGY, 1983, 129 (04) : 730 - 733
  • [9] Significance of bladder neck involvement on progression in superficial bladder cancer
    Fujii, Y
    Fukui, I
    Kihara, K
    Tsujii, T
    Ishizaka, K
    Kageyama, Y
    Kawakami, S
    Oshima, H
    [J]. EUROPEAN UROLOGY, 1998, 33 (05) : 464 - 468
  • [10] T1G3 bladder cancer: Conservative management or cystectomy?
    Gattegno, B
    [J]. EUROPEAN UROLOGY, 2004, 45 (04) : 399 - 400